Cystic Fibrosis Clinical Trial
Official title:
Effects Of Noninvasive Ventilation During The Treadmill Walking Test On Cardiorespiratory System, Walk Distance, And Thoracoabdominal Kinematics Of Patients With Cystic Fibrosis: Clinical Randomized Controlled Trial.
The purpose of this study is to evaluate the effect of noninvasive ventilation (NIV) in functional capacity of children and adolescents with cystic fibrosis.
This is an open randomized controlled crossover clinical trial. Sample selection was by
convenience and patients were screened at the Pneumology outpatient facility of the
Instituto de Medicina Integral Professor Fernando Figueira (IMIP) in Recife, Brazil.
The sample was calculated using a software developed by the MGH Mallinckrodt General
Clinical Research Center, based on the results of the first 10 volunteers, for a statistical
power of detecting differences between procedures of 80% and a significance level of 0.05. A
sample size of n=13 patients was determined, considering that the real difference between
the walk distance between procedures with and without NIV is 0.03 km and the standard
deviation of the differences in variables is 0.034 km.
All patients agreed to take part in the study by giving their informed consent, in
accordance with resolution 196/96 of the National Health Council.
Technical Procedures Patients were initially assessed for current and past conditions,
medication use and anthropometric data (height, weight and body mass index - BMI). Next, a
randomized plan was compiled using the Web Site Randomization.com, applying a generator of
random-permuted blocks to define the order in which patients would execute the 6MWT, with or
without NIV. Patients allocated to group 1 (G1) initiated the 6MWT without NIV to
subsequently perform the test with ventilatory support, since those allocated to group 2
(G2) underwent the tests in reverse order. A minimum and maximum rest period of 24 and 48
hours, respectively, was observed between tests.
Before and after the 6MWT with and without NIV, patients were assessed for variations in
compartmental chest wall volume and ventilatory pattern by optoelectronic plethysmography
(OEP), which was followed by the spirometric test. A 20-minute rest period was given after
the pulmonary function test before proceeding to the 6MWT.
6-minute walk test on the treadmill: Prior to the test, the patient was familiarized with
the treadmill (G-635, Pro Action BH-fitness- Germany) and instructed about test procedures
in accordance with ATS guidelines22. The following parameters were assessed before,
immediately after and in the 5th minute post-test: blood pressure (BP), respiratory rate
(RR), heart rate (HR), Borg's scale (BS) and peripheral O2 saturation (SpO2). HR, RR and
SpO2 were also monitored minute by minute during the test, such that a drop in SpO2 below
87% or rise in RR to more than 75% of age-predicted maximal HR were used as criteria for
interrupting the test. The test initiated with the treadmill traveling at 2.5 km/h. Every 30
seconds of the test, the examiner asked the patient if the speed could be increased,
maintained or decreased, and patients answered using previously agreed upon signals. The
speed could not exceed 7 km/h and if it was reached, the question would be re-asked in the
next 30 seconds to determine whether the speed would be maintained or reduced. After the
test, the walk distance (WD) on the treadmill was recorded.
The 6MWT performed with NIV followed the same procedures described above. However, before
the test, patients were submitted to NIV on a BiPAP mode (Synchrony- Respironics, Brazil)
for 30 minutes, as proposed by Serra et al 15, with inspiratory airway pressure (IPAP) level
of 12 cmH2O and final expiratory airway pressure (EPAP) of 6 cmH2O, which can vary by 2
cmH2O more or less depending on the patient's comfort. In the last six minutes of BiPAP the
patient performed the 6MWT with the ventilatory support.
Optoelectronic plethysmography: The individual was sitting with 89 retro-reflective sensors
at specific thoracic and abdominal points. Eight cameras were arranged around the patient
for a three-minute film of quiet breathing. The images were analyzed in a three-dimensional
polyhedric model using OEP capture software (BTS Bioengineering, Italy). The following
variables were assessed by OEP (BTS Bioengineering, Italy) before and after both tests, with
and without NIV: tidal volume, pulmonary rib cage volume, abdominal rib cage and abdominal
volume (VC, Vrcp Vrca, Vab), respiratory rate (RR), inspiratory time (Ti), expiratory time
(Te) total ventilatory cycle time (Ttot) and duty cycle, which represents the Ti/Ttot ratio.
Spirometry: Spirometry was conducted using a Microloop MK 8 spirometer (Micro Medical,
England) to assess pulmonary function response, considering a 20-minute rest period between
the spirometric test and 6MWT. Three reproducible forced maneuvers that met American
Thoracic Society criteria were performed. The highest values obtained for forced expiratory
volume in the first minute (FEV1), forced vital capacity (FVC), forced vital capacity
between 25-75% of FVC (FEF 25-75) were recorded for analysis.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |